LONG-TERM TREATMENT OF GIGANTISM WITH COMBINATION OCTREOTIDE AND BROMOCRIPTINE IN A CHILD WITH MCCUNE-ALBRIGHT SYNDROME

We report a 7 year old boy with McCune-Albright syndrome, precocious p uberty, and gigantism. Medical therapy of growth hormone excess was in itiated after it was determined that he was a poor surgical candidate secondary to fibrous dysplasia of the skull. Neither octreotide nor br omocriptine alone controlled excessive secretion of growth hormone and prolactin, but the combination of the two drugs normalized hormone le vels. Marked reduction in tumor size was observed after 3 months of co mbination therapy. He has been treated for 6 years with octreotide, an d has experienced no negative sequelae. To the best of our knowledge, this case represents the longest treatment interval of any other child receiving octreotide.